Physician profile
Jonathan D Mozena
NPI 1093757163
$13,903.35
in general payments reported to CMS, 2019-2025
31 companies · $7,388 in 2025
The $7,388 reported for 2025 was more than what 86% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $471 · 2021: $512 · 2022: $1,002 · 2023: $1,212 · 2024: $1,918 · 2025: $7,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,400 · Food and Beverage: $5,101 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,400.00 |
| Food and Beverage | $5,100.63 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,076.19 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,470.83 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $508.64 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $479.13 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $447.55 | 2019-2025 | |
| Csl Behring | $439.80 | 2019-2025 | Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $393.85 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Genentech USA, INC. | $311.11 | 2019-2025 | Xolair |
| Amgen INC. | $267.36 | 2021-2025 | Tezspire |
| Blueprint Medicines Corporation | $247.33 | 2023-2025 | Ayvakit |
| Grifols USA, LLC | $229.91 | 2019-2024 | Xembify |
| Incyte Corporation | $148.41 | 2021-2025 | Opzelura |
| Pfizer INC. | $129.54 | 2019-2024 | |
| Biocryst US Sales Co., LLC | $128.72 | 2021-2023 | Orladeyo |
| Optinose US, INC. | $124.80 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $88.95 | 2019 | |
| Kaleo, INC. | $63.72 | 2019-2022 | |
| Ionis Pharmaceuticals, INC. | $41.89 | 2025 | Dawnzera |
| Ars Pharmaceuticals Operations, INC. | $39.55 | 2025 | Neffy |
| Pharming Healthcare, INC. | $35.39 | 2022-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $32.94 | 2019-2020 | |
| Biocryst Pharmaceuticals, INC. | $30.89 | 2020 | |
| Aimmune Therapeutics, INC. | $29.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.84 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $18.59 | 2025 | Alvesco |
| Seqirus USA INC | $16.44 | 2022 | |
| Horizon Therapeutics Plc | $16.00 | 2019 | |
| Galderma Laboratories, L.P. | $15.65 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $14.22 | 2025 | Sajazir |
| Alk-Abello, INC | $13.96 | 2019 | |
| Hikma Pharmaceuticals USA | $13.46 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mozena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.